YmAbs Therapeutics (YMAB)
(Delayed Data from NSDQ)
$15.39 USD
+0.22 (1.45%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $15.41 +0.02 (0.13%) 7:32 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Y-mAbs Therapeutics, Inc. (YMAB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$20.63 | $26.00 | $11.00 | 35.99% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Y-mAbs Therapeutics, Inc. comes to $20.63. The forecasts range from a low of $11.00 to a high of $26.00. The average price target represents an increase of 35.99% from the last closing price of $15.17.
Analyst Price Targets (8 )
Broker Rating
Y-mAbs Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.59 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.67 a month ago based on seven recommendations.
Of the eight recommendations deriving the current ABR, six are Strong Buy, representing 75% of all recommendations. A month ago, Strong Buy represented 71.43%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/YMAB.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 5 | 5 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.59 | 1.59 | 1.67 | 1.67 | 1.78 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/16/2024 | Cantor Fitzgerald & Co | Li Watsek | Not Available | Strong Buy |
8/13/2024 | BMO Capital Markets | Etzer Darout | Strong Buy | Strong Buy |
8/13/2024 | Canaccord Genuity | John L Newman | Not Available | Strong Buy |
8/13/2024 | H.C. Wainwright & Co. | Robert Burns | Strong Buy | Strong Buy |
8/12/2024 | Wedbush Securities | David M Nierengarten | Strong Buy | Strong Buy |
6/28/2024 | Truist Securities | Nicole Germino | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.59 |
ABR (Last week) | 1.59 |
# of Recs in ABR | 8 |
Average Target Price | $20.63 |
LT Growth Rate | 42.80% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 253 |
Current Quarter EPS Est: | -0.10 |